{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:38:29Z","timestamp":1695274709409},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Minimal Change Glomerulopathie ist eine glomerul\u00e4re Erkrankung, die sich klinisch typischerweise als akut auftretendes nephrotisches Syndrom manifestiert. Die Diagnose wird bei fehlenden lichtmikroskopischen Ver\u00e4nderungen, jedoch typischem elektronenmikroskopischem Befund eines meist vollst\u00e4ndigen Verlustes der podozyt\u00e4ren Fu\u00dfforts\u00e4tze mittels Nierenbiopsie gestellt. Das zumeist gute Ansprechen auf immunsuppressive Ma\u00dfnahmen, insbesondere Glukokortikoide, lassen eine autoimmune Krankheitsgenese annehmen. Trotz allgemein guter Prognose k\u00f6nnen steroid-abh\u00e4ngige, steroid-resistente und h\u00e4ufig relapsierende Verl\u00e4ufe den Krankheitsverlauf komplizieren und den Einsatz alternativer Immunsuppressiva erforderlich machen. Die \u00d6sterreichische Gesellschaft f\u00fcr Nephrologie (\u00d6GN) stellt hier einen gemeinsamen Konsens dar\u00fcber vor, wie erwachsene PatientInnen mit Minimal Change Glomerulopathie am besten diagnostiziert und behandelt werden k\u00f6nnen.<\/jats:p>","DOI":"10.1007\/s00508-023-02258-5","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:01:56Z","timestamp":1695214916000},"page":"628-637","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostik und Therapie der Minimal Change Glomerulopathie beim Erwachsenen\u00a0\u2013 2023","Diagnosis and treatment of Minimal Change Disease in adults\u20142023"],"prefix":"10.1007","volume":"135","author":[{"given":"Philipp","family":"Gauckler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Regele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Lhotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmgard","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"12","key":"2258_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nrneph.2016.147","volume":"12","author":"RJ Maas","year":"2016","unstructured":"Maas\u00a0RJ, Deegens\u00a0JK, Smeets\u00a0B, Moeller\u00a0MJ, Wetzels\u00a0JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12(12):768\u201376.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2258_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1053\/j.ajkd.2019.12.019","volume":"75","author":"W Ahn","year":"2020","unstructured":"Ahn\u00a0W, Bomback\u00a0AS. Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults: core curriculum 2020. Am J Kidney Dis. 2020;75(6):955\u201364.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2258_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp\u00a0JB, Anders\u00a0HJ, Susztak\u00a0K, Podesta\u00a0MA, Remuzzi\u00a0G, Hildebrandt\u00a0F, et\u00a0al. Podocytopathies. Nat Rev Dis Primers. 2020;6(1):68.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2258_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli\u00a0M, Massella\u00a0L, Ruggiero\u00a0B, Emma\u00a0F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2258_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene\u00a0A, Vachin\u00a0P, Sendeyo\u00a0K, Oniszczuk\u00a0J, Zhang\u00a0SY, Henique\u00a0C, et al. NEPHRUTIX: a\u00a0randomized, double-blind, placebo vs rituximab-controlled trial assessing T\u2011cell subset changes in minimal change nephrotic syndrome. J\u00a0Autoimmun. 2018;88:91\u2013102.","journal-title":"J Autoimmun"},{"issue":"7880","key":"2258_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub\u00a0RJ. Pathogenesis of lipoid nephrosis: a\u00a0disorder of T\u2011cell function. Lancet. 1974;2(7880):556\u201360.","journal-title":"Lancet"},{"issue":"11","key":"2258_CR7","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.autrev.2020.102671","volume":"19","author":"P Gauckler","year":"2020","unstructured":"Gauckler\u00a0P, Shin\u00a0JI, Alberici\u00a0F, Audard\u00a0V, Bruchfeld\u00a0A, Busch\u00a0M, et\u00a0al. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis\u2014what is known and what is still unknown? Autoimmun Rev. 2020;19(11):102671.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2258_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts\u00a0AJB, Keller\u00a0KH, Lerner\u00a0G, Rosales\u00a0I, Collins\u00a0AB, Sekulic\u00a0M, et\u00a0al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a\u00a0novel autoimmune etiology. J\u00a0Am Soc Nephrol. 2022;33(1):238\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 6","key":"2258_CR9","first-page":"vi52","volume":"18","author":"RJ Glassock","year":"2003","unstructured":"Glassock\u00a0RJ. Secondary minimal change disease. Nephrol Dial Transplant. 2003;18(Suppl 6):vi52\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2258_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.34067\/KID.0005372021","volume":"2","author":"TN Caza","year":"2021","unstructured":"Caza\u00a0TN, Cassol\u00a0CA, Messias\u00a0N, Hannoudi\u00a0A, Haun\u00a0RS, Walker\u00a0PD, et al. Glomerular disease in temporal association with SARS-CoV\u20112 vaccination: a\u00a0series of 29 cases. Kidney360. 2021;2(11):1770\u201380.","journal-title":"Kidney360"},{"issue":"1","key":"2258_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12882-020-02066-3","volume":"21","author":"K Horikoshi","year":"2020","unstructured":"Horikoshi\u00a0K, Sakai\u00a0N, Yamamoto\u00a0N, Ogura\u00a0H, Sato\u00a0K, Miyagawa\u00a0T, et\u00a0al. A\u00a0case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a\u00a0case report. BMC Nephrol. 2020;21(1):416.","journal-title":"BMC Nephrol"},{"key":"2258_CR12","doi-asserted-by":"publisher","unstructured":"Kronbichler A, Jung SY, Kim MS, Shin JI. Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: a\u00a0VigiBase analysis. Kidney Int. 2021. https:\/\/doi.org\/10.1016\/j.kint.2021.11.013.","DOI":"10.1016\/j.kint.2021.11.013"},{"issue":"Suppl 133[6]","key":"2258_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.55563\/clinexprheumatol\/5harco","volume":"39","author":"J Lang","year":"2021","unstructured":"Lang\u00a0J, Shi\u00a0X, Ma\u00a0Y, Zou\u00a0L, Fei\u00a0Y, Chen\u00a0L. Primary Sjogren\u2019s syndrome with minimal change disease: case series and literature review. Clin Exp Rheumatol. 2021;39(Suppl 133[6]):226\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2258_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd\u00a0JM, Gizaw\u00a0AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89(3):720.","journal-title":"Kidney Int"},{"issue":"5","key":"2258_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ckj\/sfs081","volume":"5","author":"M Koya","year":"2012","unstructured":"Koya\u00a0M, Pichler\u00a0R, Jefferson\u00a0JA. Minimal-change disease secondary to etanercept. Clin Kidney\u00a0J. 2012;5(5):420\u20133.","journal-title":"Clin Kidney J"},{"key":"2258_CR16","doi-asserted-by":"publisher","unstructured":"Canney M, Atiquzzaman M, Cunningham AM, Zheng Y, Er L, Hawken S, et al. A\u00a0population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination. J\u00a0Am Soc Nephrol. 2022. https:\/\/doi.org\/10.1681\/ASN.2022030258.","DOI":"10.1681\/ASN.2022030258"},{"issue":"5","key":"2258_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","volume":"54","author":"M Abdel-Hafez","year":"2009","unstructured":"Abdel-Hafez\u00a0M, Shimada\u00a0M, Lee\u00a0PY, Johnson\u00a0RJ, Garin\u00a0EH. Idiopathic nephrotic syndrome and atopy: is there a\u00a0common link? Am J Kidney Dis. 2009;54(5):945\u201353.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2258_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ndt\/gfh719","volume":"20","author":"AJ Branten","year":"2005","unstructured":"Branten\u00a0AJ, Vervoort\u00a0G, Wetzels\u00a0JF. Serum creatinine is a\u00a0poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005;20(4):707\u201311.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2258_CR19","first-page":"345","volume":"101","author":"DR Prasad","year":"1977","unstructured":"Prasad\u00a0DR, Zimmerman\u00a0SW, Burkholder\u00a0PM. Immunohistologic features of minimal-change nephrotic syndrome. Arch Pathol Lab Med. 1977;101(7):345\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"4S","key":"2258_CR20","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013S276.","journal-title":"Kidney Int"},{"issue":"5","key":"2258_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","volume":"69","author":"RJ Maas","year":"2017","unstructured":"Maas\u00a0RJ, Deegens\u00a0JK, Beukhof\u00a0JR, Reichert\u00a0LJ, Ten Dam\u00a0MA, Beutler\u00a0JJ, et\u00a0al. The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a\u00a0case series. Am J Kidney Dis. 2017;69(5):637\u201346.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2258_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/ki.1986.130","volume":"29","author":"F Nolasco","year":"1986","unstructured":"Nolasco\u00a0F, Cameron\u00a0JS, Heywood\u00a0EF, Hicks\u00a0J, Ogg\u00a0C, Williams\u00a0DG. Adult-onset minimal change nephrotic syndrome: a\u00a0long-term follow-up. Kidney Int. 1986;29(6):1215\u201323.","journal-title":"Kidney Int"},{"issue":"11","key":"2258_CR23","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1093\/oxfordjournals.ndt.a027136","volume":"11","author":"SK Mak","year":"1996","unstructured":"Mak\u00a0SK, Short\u00a0CD, Mallick\u00a0NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant. 1996;11(11):2192\u2013201.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2258_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman\u00a0M, Crew\u00a0RJ, Valeri\u00a0A, Busch\u00a0J, Stokes\u00a0B, Markowitz\u00a0G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2258_CR25","doi-asserted-by":"publisher","unstructured":"Lionaki S, Mantios E, Tsoumbou I, Marinaki S, Makris G, Liapis G, et\u00a0al. Clinical characteristics and outcomes of adults with nephrotic syndrome due to minimal change disease. J\u00a0Clin Med. 2021;10(16). https:\/\/doi.org\/10.3390\/jcm10163632.","DOI":"10.3390\/jcm10163632"},{"issue":"5","key":"2258_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.kint.2018.04.024","volume":"94","author":"A Meyrier","year":"2018","unstructured":"Meyrier\u00a0A, Niaudet\u00a0P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94(5):861\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"2258_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin\u00a0BA, Ayoob\u00a0R, Smoyer\u00a0WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2258_CR28","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1681\/ASN.2006111300","volume":"18","author":"RJ Glassock","year":"2007","unstructured":"Glassock\u00a0RJ. Prophylactic anticoagulation in nephrotic syndrome: a\u00a0clinical conundrum. J\u00a0Am Soc Nephrol. 2007;18(8):2221\u20135.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2258_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","volume":"117","author":"BK Mahmoodi","year":"2008","unstructured":"Mahmoodi\u00a0BK, ten Kate\u00a0MK, Waanders\u00a0F, Veeger\u00a0NJ, Brouwer\u00a0JL, Vogt\u00a0L, et\u00a0al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a\u00a0large retrospective cohort study. Circulation. 2008;117(2):224\u201330.","journal-title":"Circulation"},{"key":"2258_CR30","doi-asserted-by":"publisher","unstructured":"Shinkawa K, Yoshida S, Seki T, Yanagita M, Kawakami K. Risk factors of venous thromboembolism in patients with nephrotic syndrome: a\u00a0retrospective cohort study. Nephrol Dial Transplant. 2020. https:\/\/doi.org\/10.1093\/ndt\/gfaa134.","DOI":"10.1093\/ndt\/gfaa134"},{"issue":"4","key":"2258_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","volume":"3","author":"DJ Sexton","year":"2018","unstructured":"Sexton\u00a0DJ, de Freitas\u00a0DG, Little\u00a0MA, McHugh\u00a0T, Magee\u00a0C, Conlon\u00a0PJ, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep. 2018;3(4):784\u201393.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2258_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas\u00a0NR, Lawrence\u00a0C, Condon\u00a0M, Sood\u00a0B, Warwicker\u00a0P, Brown\u00a0H, et al. Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a\u00a0multicenter, randomized, controlled trial. Clin J Am Soc Nephrol. 2020;15(2):209\u201318.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2258_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000495352","volume":"49","author":"T Ozeki","year":"2019","unstructured":"Ozeki\u00a0T, Katsuno\u00a0T, Hayashi\u00a0H, Kato\u00a0S, Yasuda\u00a0Y, Ando\u00a0M, et al. Short-term steroid regimen for adult steroid-sensitive minimal change disease. Am J Nephrol. 2019;49(1):54\u201363.","journal-title":"Am J Nephrol"},{"key":"2258_CR34","unstructured":"Minimal change disease. In: Ponticelli\u00a0C, Glassock\u00a0RJ, Coppo\u00a0R, Hrsg. Treatment of primary glomerulonephritis Oxford University Press; 2019."},{"issue":"5","key":"2258_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2012070734","volume":"24","author":"J Hogan","year":"2013","unstructured":"Hogan\u00a0J, Radhakrishnan\u00a0J. The treatment of minimal change disease in adults. J\u00a0Am Soc Nephrol. 2013;24(5):702\u201311.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2258_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","volume":"39","author":"M Nakayama","year":"2002","unstructured":"Nakayama\u00a0M, Katafuchi\u00a0R, Yanase\u00a0T, Ikeda\u00a0K, Tanaka\u00a0H, Fujimi\u00a0S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39(3):503\u201312.","journal-title":"Am J Kidney Dis"},{"key":"2258_CR37","volume-title":"Supporting evidence document: CNI protocol for MCD and FSGS","author":"BCRenal","year":"2019","unstructured":"BCRenal. Supporting evidence document: CNI protocol for MCD and FSGS. 2019."},{"issue":"1","key":"2258_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1681\/ASN.2019050546","volume":"32","author":"HJ Chin","year":"2021","unstructured":"Chin\u00a0HJ, Chae\u00a0DW, Kim\u00a0YC, An\u00a0WS, Ihm\u00a0C, Jin\u00a0DC, et al. Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J\u00a0Am Soc Nephrol. 2021;32(1):199\u2013210.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2258_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","volume":"72","author":"DC Cattran","year":"2007","unstructured":"Cattran\u00a0DC, Alexopoulos\u00a0E, Heering\u00a0P, Hoyer\u00a0PF, Johnston\u00a0A, Meyrier\u00a0A, et\u00a0al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007;72(12):1429\u201347.","journal-title":"Kidney Int"},{"issue":"3","key":"2258_CR40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali\u00a0H, Bouachi\u00a0K, Audard\u00a0V, Remy\u00a0P, Lang\u00a0P, Mojaat\u00a0R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):511\u20136.","journal-title":"Kidney Int"},{"issue":"10","key":"2258_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/nep.12744","volume":"21","author":"E Papakrivopoulou","year":"2016","unstructured":"Papakrivopoulou\u00a0E, Shendi\u00a0AM, Salama\u00a0AD, Khosravi\u00a0M, Connolly\u00a0JO, Trompeter\u00a0R. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology (Carlton). 2016;21(10):893\u2013900.","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"2258_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004670000523","volume":"16","author":"K Latta","year":"2001","unstructured":"Latta\u00a0K, von Schnakenburg\u00a0C, Ehrich\u00a0JH. A\u00a0meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16(3):271\u201382.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2258_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000464475","volume":"45","author":"LC Brown","year":"2017","unstructured":"Brown\u00a0LC, Jobson\u00a0MA, Payan Schober\u00a0F, Chang\u00a0EH, Falk\u00a0RJ, Nachman\u00a0PH, et\u00a0al. The evolving role of Rituximab in adult minimal change glomerulopathy. Am J Nephrol. 2017;45(4):365\u201372.","journal-title":"Am J Nephrol"},{"key":"2258_CR44","doi-asserted-by":"publisher","unstructured":"Diebold M, Locher E, Boide P, Enzler-Tschudy A, Faivre A, Fischer I, et al. Incidence of new onset glomerulonephritis after SARS-CoV\u20112 mRNA vaccination is not increased. Kidney Int. 2022. https:\/\/doi.org\/10.1016\/j.kint.2022.08.021.","DOI":"10.1016\/j.kint.2022.08.021"},{"issue":"8","key":"2258_CR45","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.transproceed.2003.10.056","volume":"35","author":"CI Jan","year":"2003","unstructured":"Jan\u00a0CI, Chen\u00a0A, Sun\u00a0GH, Yu\u00a0DS, Yen\u00a0CY, Chen\u00a0JS, et al. Recurrent minimal change disease post-allograft renal transplant. Transplant Proc. 2003;35(8):2888\u201390.","journal-title":"Transplant Proc"},{"issue":"5","key":"2258_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1034\/j.1399-0012.2002.02023.x","volume":"16","author":"AA Zafarmand","year":"2002","unstructured":"Zafarmand\u00a0AA, Baranowska-Daca\u00a0E, Ly\u00a0PD, Tsao\u00a0CC, Choi\u00a0YJ, Suki\u00a0WN, et al. De novo minimal change disease associated with reversible post-transplant nephrotic syndrome. A\u00a0report of five cases and review of literature. Clin Transplant. 2002;16(5):350\u201361.","journal-title":"Clin Transplant"},{"issue":"8","key":"2258_CR47","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/nep.13871","volume":"26","author":"S Gleeson","year":"2021","unstructured":"Gleeson\u00a0S, Cardoso\u00a0F, Lightstone\u00a0L, Webster\u00a0P, Munro\u00a0K, Cairns\u00a0T. A\u00a0new approach to de novo minimal change disease in pregnancy. Nephrology (Carlton). 2021;26(8):692\u20133.","journal-title":"Nephrology (Carlton)"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02258-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:17:34Z","timestamp":1695215854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02258-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02258-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Gauckler, H.\u00a0Regele, K.\u00a0Eller, M.D.\u00a0S\u00e4emann, K.\u00a0Lhotta, E.\u00a0Zitt, I.\u00a0Neumann, M.\u00a0Rudnicki, B.\u00a0Odler, A.\u00a0Kronbichler und M.\u00a0Windpessl geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}